Ascletis Pharma, a joint venture between entrepreneurs in the U.S. and China, focuses on developing and commercializing innovative drugs in areas such as NASH, cancer lipid metabolism, viral hepatitis, and HIV/AIDS. Led by a management team with deep expertise, Ascletis covers the entire value chain from discovery to commercialization and aims to establish a sustainable business in the Chinese pharmaceutical marketplace. Additionally, through its subsidiary Gannex, Ascletis is dedicated to the research and development of new drugs for NASH and has multiple clinical stage drug candidates.